Biotech entity
All 1 tracked stories fall under one category: fda-approval. NG-TEST Aci is most often covered alongside FDA, which appears in 1 of these 1 story. The 7 average consequence score is above the beat benchmark of 6 in the same window.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: fda-approval. NG-TEST Aci is most often covered alongside FDA, which appears in 1 of these 1 story. The 7 average consequence score is above the beat benchmark of 6 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Biotech story that mention NG-TEST Aci, all published on February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NG-TEST Aci. Shared-story counts are live from our verified record — not editorial picks.
NG Biotech and partner Hardy Diagnostics have received FDA Breakthrough Device Designation for two rapid diagnostic tests targeting Candida auris and Acinetobacter baumannii. These assays aim to provide near-instant identification of high-priority antimicrobial-resistant pathogens to improve hospital infection control.
NG-TEST Aci is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
